Ratings Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 14:51:52 12/12/2024 GMT			5-day change	1st Jan Change
1,495.75 ^DKK	-2.62%		-3.38%	-30.44%

12-11	Genmab A/S - Special Call
12-09	Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial	MT

Summary: Genmab A/S

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: Genmab A/S

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses: Genmab A/S

With an enterprise value anticipated at 4 times the sales for the current fiscal year, the company turns out to be overvalued.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings Chart: Genmab A/S

Source: Surperformance

ESG chart: Genmab A/S

Source: Refinitiv

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
GENMAB A/S		14.3B
VERTEX PHARMACEUTICALS INCORPORATED		121B
REGENERON PHARMACEUTICALS, INC.		83.17B
ARGENX SE		36.73B
BIONTECH SE		28.61B
WUXI APPTEC CO., LTD.		22.76B
BEIGENE, LTD.	-	19.59B
INSMED INCORPORATED	-	13.27B
NEUROCRINE BIOSCIENCES, INC.		12.98B
Average		39.11B
Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

A-

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes